盘后公告：领益智造等四家上市公司集中发布重大事项公告 对于A股投资者来说，盘后公告从来都是不容错过的"信息富矿"——毕竟这些非交易时段披露的重大事项，往往藏着影响公司股价的关键信号，要么是资产 重组的重磅利好，要么是业务突破的实质进展，甚至可能是改变公司发展轨迹的重要决策。2025年11月底到12月初，A股市场就迎来了一波"公告密集潮"， 领益智造、嘉戎技术、恩捷股份、恒瑞医药四家各领域龙头公司集中发声，分别抛出了资产收购调整、重大资产重组、新药临床获批等关键信息，每一条都 值得投资者仔细琢磨。而这背后，离不开2025年新实施的信息披露新规保驾护航，让公告披露更规范、信息传递更及时。 一、政策护航：2025年信披新规落地，公告披露更规范透明 这四家公司能集中、清晰地披露重大事项，离不开2025年实施的信息披露新规的规范。2025年2月28日，证监会审议通过了新修订的《上市公司信息披露管 理办法》（证监会令第226号），并于7月1日正式施行 。新规明确要求，上市公司披露的信息必须"真实、准确、完整、简明清晰、通俗易懂"，不得有虚假 记载或误导性陈述，而且重大事件要"立即披露"，说明事件起因、状态和影响，让投资者 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) achieved record high revenue and net profit driven by innovative drugs, with a significant stock price increase recently [1][2][3] Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% year-on-year [1] - The company's innovative drug sales revenue reached 13.892 billion yuan, contributing over half of total sales revenue, with a year-on-year growth of 30.60% [3][4] Research and Development - Heng Rui Medicine's R&D investment reached a historical high of 8.228 billion yuan in 2024, representing a year-on-year increase of 33.79%, accounting for 29.40% of revenue [1][4] - Cumulatively, the company has invested over 44 billion yuan in R&D to date [1] Innovation and Product Development - The company expects over 40 innovative products to be approved for market in the next three years, covering various therapeutic areas including oncology and cardiovascular diseases [7][9] - In 2024, 10 innovative products were approved, including four first-class innovative drugs [7][8] Internationalization and Business Development - Heng Rui Medicine has initiated over 20 overseas clinical trials in countries such as the US, Europe, and Japan, with several products entering Phase III trials [11][12] - The company has engaged in 13 licensing transactions with global partners, with a potential total transaction value of approximately 14 billion USD [12][13]